Encysive To Enter Dispute Resolution With FDA Over Third Thelin “Approvable” Letter
Company asserts that FDA’s data analysis of STRIDE-2 trial for Thelin does not follow special protocol assessment agreement.
Company asserts that FDA’s data analysis of STRIDE-2 trial for Thelin does not follow special protocol assessment agreement.